GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z3) » Definitions » Forward PE Ratio

Sonoma Pharmaceuticals (STU:O8Z3) Forward PE Ratio : 0.00 (As of Jun. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Forward PE Ratio?

Sonoma Pharmaceuticals's Forward PE Ratio for today is 0.00.

Sonoma Pharmaceuticals's PE Ratio without NRI for today is 0.00.

Sonoma Pharmaceuticals's PE Ratio for today is 0.00.


Sonoma Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Sonoma Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Forward PE Ratio Chart

Sonoma Pharmaceuticals Annual Data
Trend
Forward PE Ratio

Sonoma Pharmaceuticals Quarterly Data
Forward PE Ratio

Competitive Comparison of Sonoma Pharmaceuticals's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Forward PE Ratio falls into.



Sonoma Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Sonoma Pharmaceuticals  (STU:O8Z3) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Sonoma Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals (STU:O8Z3) Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals (STU:O8Z3) Headlines

No Headlines